1Alter MJ, Favero MS, Maynard JE. Impact of infection control startegies on the incidence of dialysis associated hepatitis in the United States. J Infect Dis,1986,153:1149-1151.
3Sakamoto N, Enomoto N, Marumo F, et al. Prevalence of hepati tis C virus infection among long term hemodialysis patients: detection of hepatitis C virus RNA in plasma. J Med Virol, 1993,39: 1115.
4Fernandez JL, Pino N, Lef L, et al. Serum hepatitis C virus RNA in anti-HCV negative hemodialysis patients. Dial Transplant, 1996,25:14-19.
5Conway M, Catterall AP, Brown EA, et al. Prevalence of antibodies to hepatitis C virus in dialysis patients and transplant recipients with possible routes of transmission. Nephrol Dial Transplant, 1992,7: 1226-1229.
6Pol S, Romeo R, Zins B, et al. Hepatitis C virus RNA in antiHCV positive hemodialysis patients: significance and therapeutic implications. Kindney Int, 1993,44:1097-1100.
7Jollif C. Classification and interpretation of paragon serum protein electrophoresis patterns. Paragon, 1991,1: 13-18.
6Scott BK,Christian GR,Pat M,et al.Protocolized anemia management with erythropoietin in hemodialysis patients:a randomized controlled trial.J Am Soc Nephrol,2003,14:2 654-2 611.
7Stephanie H,Ross MA,Carol M,et al.A multidisciplinary approach to the control of the calcium phosphate product.Dialysis and Transplantation,1999,28:309-313.
8Trepo C,Pradat P.Hepatitis C virus infection in Western Europe.J Hepatol,1999,31(suppl 1):80-83.
9Chen KS,Lo SK,Lee N,et al.Superinfection with hepatitis C virus in hemodialysis patients with hepatitis B surface antigenemia:its prevalence and clinical significance in Taiwan.Nephron,1996,73:158-164.
10Forns X,Fernandez-Llama P,Pons M,et al.Incidence and risk factors of hepatitis C virus infection in a haemodialysis unit.Nephrol Dial Transplant,1997,12:736-740.
